MMRGlobal Goes Into 2012 Highlighting $43 Million in Projected Revenues From ... MarketWatch (press release) ... has more than 40 patents issued, pending and or applied for worldwide, including patents pertaining to the Company's FavId(R)/Specifid(TM) vaccine trials and anti-CD20 antibody assets, the second widely believed to be a first cousin to Rituximab. |
